- Patent Title: Substituted imidazoles as bombesin receptor subtype-3 modulators
-
Application No.: US13327093Application Date: 2011-12-15
-
Publication No.: US08318767B2Publication Date: 2012-11-27
- Inventor: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.-C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
- Applicant: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.-C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
- Applicant Address: US NJ Rahway US NY Albany
- Assignee: Merck Sharp & Dohme Corp,Albany Molecular Research, Inc.
- Current Assignee: Merck Sharp & Dohme Corp,Albany Molecular Research, Inc.
- Current Assignee Address: US NJ Rahway US NY Albany
- Agent Baerbel R. Brown; John C. Todaro
- Main IPC: A61K31/437
- IPC: A61K31/437 ; A61K31/4439 ; A61K31/427 ; A61K31/4155 ; C07D417/10 ; C07D233/64 ; C07D471/04 ; C07D401/14 ; C07D401/10 ; C07D403/10
Abstract:
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
Public/Granted literature
- US20120088788A1 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS Public/Granted day:2012-04-12
Information query
IPC分类:
